These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
589 related articles for article (PubMed ID: 16488666)
41. Exploring the frontiers of therapeutic exon skipping for Duchenne muscular dystrophy by double targeting within one or multiple exons. Aartsma-Rus A; Kaman WE; Weij R; den Dunnen JT; van Ommen GJ; van Deutekom JC Mol Ther; 2006 Sep; 14(3):401-7. PubMed ID: 16753346 [TBL] [Abstract][Full Text] [Related]
42. Full-length dystrophin cDNA transfer into skeletal muscle of adult mdx mice by electroporation. Murakami T; Nishi T; Kimura E; Goto T; Maeda Y; Ushio Y; Uchino M; Sunada Y Muscle Nerve; 2003 Feb; 27(2):237-41. PubMed ID: 12548532 [TBL] [Abstract][Full Text] [Related]
43. Electroporation of corrective nucleic acids (CNA) in vivo to promote gene correction in dystrophic muscle. Kapsa RM; Wong SH; Quigley AF Methods Mol Biol; 2008; 423():405-19. PubMed ID: 18370218 [TBL] [Abstract][Full Text] [Related]
44. A highly functional mini-dystrophin/GFP fusion gene for cell and gene therapy studies of Duchenne muscular dystrophy. Li S; Kimura E; Ng R; Fall BM; Meuse L; Reyes M; Faulkner JA; Chamberlain JS Hum Mol Genet; 2006 May; 15(10):1610-22. PubMed ID: 16595609 [TBL] [Abstract][Full Text] [Related]
45. Chimeric RNA/ethylene-bridged nucleic acids promote dystrophin expression in myocytes of duchenne muscular dystrophy by inducing skipping of the nonsense mutation-encoding exon. Surono A; Van Khanh T; Takeshima Y; Wada H; Yagi M; Takagi M; Koizumi M; Matsuo M Hum Gene Ther; 2004 Aug; 15(8):749-57. PubMed ID: 15319032 [TBL] [Abstract][Full Text] [Related]
46. Development of antisense-mediated exon skipping as a treatment for duchenne muscular dystrophy. Heemskerk H; de Winter CL; van Ommen GJ; van Deutekom JC; Aartsma-Rus A Ann N Y Acad Sci; 2009 Sep; 1175():71-9. PubMed ID: 19796079 [TBL] [Abstract][Full Text] [Related]
47. Bioinformatic and functional optimization of antisense phosphorodiamidate morpholino oligomers (PMOs) for therapeutic modulation of RNA splicing in muscle. Popplewell LJ; Graham IR; Malerba A; Dickson G Methods Mol Biol; 2011; 709():153-78. PubMed ID: 21194027 [TBL] [Abstract][Full Text] [Related]
48. Enhanced in vivo delivery of antisense oligonucleotides to restore dystrophin expression in adult mdx mouse muscle. Wells KE; Fletcher S; Mann CJ; Wilton SD; Wells DJ FEBS Lett; 2003 Sep; 552(2-3):145-9. PubMed ID: 14527677 [TBL] [Abstract][Full Text] [Related]
49. Dystrophin expression in host muscle following transplantation of muscle precursor cells modified with the phiC31 integrase. Quenneville SP; Chapdelaine P; Rousseau J; Tremblay JP Gene Ther; 2007 Mar; 14(6):514-22. PubMed ID: 17167499 [TBL] [Abstract][Full Text] [Related]
50. Wild-type mouse models to screen antisense oligonucleotides for exon-skipping efficacy in Duchenne muscular dystrophy. Cao L; Han G; Gu B; Yin H PLoS One; 2014; 9(11):e111079. PubMed ID: 25365558 [TBL] [Abstract][Full Text] [Related]
51. Efficient and fast functional screening of microdystrophin constructs in vivo and in vitro for therapy of duchenne muscular dystrophy. Jørgensen LH; Larochelle N; Orlopp K; Dunant P; Dudley RW; Stucka R; Thirion C; Walter MC; Laval SH; Lochmüller H Hum Gene Ther; 2009 Jun; 20(6):641-50. PubMed ID: 19239382 [TBL] [Abstract][Full Text] [Related]
52. Intravenous infusion of an antisense oligonucleotide results in exon skipping in muscle dystrophin mRNA of Duchenne muscular dystrophy. Takeshima Y; Yagi M; Wada H; Ishibashi K; Nishiyama A; Kakumoto M; Sakaeda T; Saura R; Okumura K; Matsuo M Pediatr Res; 2006 May; 59(5):690-4. PubMed ID: 16627883 [TBL] [Abstract][Full Text] [Related]
53. DMD pseudoexon mutations: splicing efficiency, phenotype, and potential therapy. Gurvich OL; Tuohy TM; Howard MT; Finkel RS; Medne L; Anderson CB; Weiss RB; Wilton SD; Flanigan KM Ann Neurol; 2008 Jan; 63(1):81-9. PubMed ID: 18059005 [TBL] [Abstract][Full Text] [Related]
54. AAV vector-mediated microdystrophin expression in a relatively small percentage of mdx myofibers improved the mdx phenotype. Yoshimura M; Sakamoto M; Ikemoto M; Mochizuki Y; Yuasa K; Miyagoe-Suzuki Y; Takeda S Mol Ther; 2004 Nov; 10(5):821-8. PubMed ID: 15509500 [TBL] [Abstract][Full Text] [Related]